- Open
- 8.45
- High
- 8.60
- Low
- 8.30
- Close
- 8.39
- Change
- -0.10 (-1.19%)
- Volume
- 1,874,226
| 23 Jul 2026 | 11:05:13 | Notification of major holdings |
| 22 Jul 2026 | 07:00:03 | Notification of Major Holdings |
| 21 Jul 2026 | 07:00:04 | Notice of Allowance for POLB 001 patent in Israel |
| 14 Jul 2026 | 07:00:05 | Placing to raise £3.5 million |
| 13 Jul 2026 | 07:00:10 | First patient dosed in POLB 001 TOPICAL trial |
| 30 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 22 Jun 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 20 May 2023 | Annual Report and Accounts (to 2022-12-31) |
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company focused on developing medicines to address unmet medical needs, particularly in the area of infectious diseases. Its clinical programs target large addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS). The company aims to progress its pipeline programs cost-effectively to position them for potential partnering and commercialization. Poolbeg operates primarily in the research and development phase, with ongoing projects such as POLB 001, which is being developed for CRS.
| 23 Jul 2026 | 11:05:13 | Notification of major holdings |
| 22 Jul 2026 | 07:00:03 | Notification of Major Holdings |
| 21 Jul 2026 | 07:00:04 | Notice of Allowance for POLB 001 patent in Israel |
| 14 Jul 2026 | 07:00:05 | Placing to raise £3.5 million |
| 13 Jul 2026 | 07:00:10 | First patient dosed in POLB 001 TOPICAL trial |
| 30 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 22 Jun 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 20 May 2023 | Annual Report and Accounts (to 2022-12-31) |
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company focused on developing medicines to address unmet medical needs, particularly in the area of infectious diseases. Its clinical programs target large addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS). The company aims to progress its pipeline programs cost-effectively to position them for potential partnering and commercialization. Poolbeg operates primarily in the research and development phase, with ongoing projects such as POLB 001, which is being developed for CRS.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £79.66bn | +0.3% | |
| £1.61bn | -0.2% | |
POLBPoolbeg Pharma PLC | £42m | +1.6% |
| £37m | — | |
| £36m | +0.7% | |
| £17m | -0.4% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £79.66bn | +0.3% | |
| £1.61bn | -0.2% | |
POLBPoolbeg Pharma PLC | £42m | +1.6% |
| £37m | — | |
| £36m | +0.7% | |
| £17m | -0.4% |
